Benzinga | Apr 20, 2021 10:38AM EDT

Barrington Research Maintains Outperform on Haemonetics, Lowers Price Target to $91

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $140 to $91.